ABBV
AbbVie Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 25 to Mar 4 ▼ 3 days of insider sells: $10.7M by 2 insiders, avg $232.17
- May 1 to May 15 ▲ 2 buys: Ro Khanna bought $15,001 - $50,000, last disclosed Jun 11
- Jun 30 ▲ 5 funds open new positions (13F)
- Aug 13 ▲ Wolfe Research upgrades
- Aug 14 ▼ 1 insider sell $8.2M at $250.00
- Sep 4 to Sep 14 ▼ 2 sells: Ro Khanna, Pete Sessions sold $15,001 - $50,000, last disclosed Oct 9
- Sep 28 Arcturus Therapeutics, Inc. v. AbbVie Inc. et al
- Oct 7 ▲ Ro Khanna bought $15,001 - $50,000, last disclosed Nov 9
- Oct 21 Trial readout: Results Pending: Eluxadoline (Phase 2), Completed 65d ago
- Oct 29 ▲ The D.C. District Court granted AbbVie partial summary judgment, rul…
- Oct 30 ▲ AbbVie reported Q3 2026 adjusted diluted EPS of $3.82, beating the $…
- Nov 9 ▼ 1 insider sell $11.9M at $293.60
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $30.8M.
- InstitutionsBULLISH
Q2 2026: 57 added (5 new), 34 trimmed or exited. Largest new: Gqg Partners $483.6M, Point72 Asset Management, $92.3M.
- AnalystsBULLISH
31 of 38 rate it Buy or better. Median target $317.00 (+8%).
- Short sellersSTEADY
Short interest +1.5% to 15.81M shares. 3.3 days to cover, ≈0.9% of shares.
- TrendUPTREND
7% above its 50-day average. New closing high $295.03 on Nov 13.
- SocialQUIET
Crowd 50° (neutral) this week from 8 mentions: 0 bullish, 0 bearish. No setup is alerting. Excludes 1 subscriber-only day.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | TRIM | $1.3B |
| Boston Partners | ADD | $1.2B |
| CITADEL ADVISORS LLC | DOUBLED | $797.6M |
| MARSHALL WACE, LLP | DOUBLED | $752.5M |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | DOUBLED | $726.1M |
| TD ASSET MANAGEMENT INC | TRIM | $648.8M |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | $597.6M |
| D. E. Shaw & Co., Inc. | DOUBLED | $529.0M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
38 analystsPrice is inside the target range. Median implies +8%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 2, 2026 | UBS MAINTAIN | Neutral |
| Nov 2, 2026 | Leerink Partners MAINTAIN | Outperform |
| Nov 2, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Nov 2, 2026 | Guggenheim MAINTAIN | Buy |
| Nov 2, 2026 | Wells Fargo MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Nov 12, 2026 | GIFT | 3,450 sh |
Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Nov 9, 2026 | EXERCISE | $2.3M |
Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Nov 9, 2026 | SELL | $11.9M |
Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Nov 9, 2026 | EXERCISE | $1.8M |
Quaggin Susan E Director Sep 30, 2026 | AWARD | $15.4K |
RAPP EDWARD J Director Sep 30, 2026 | AWARD | $33.7K |
Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER Aug 14, 2026 | EXERCISE | $2.6M |
Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER Aug 14, 2026 | SELL | $8.2M |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
22 filings · 8 bullish · 1 bearish · 1 mixed · 12 neutral- NEUTRAL 144Nov 9, 2026
Jeffrey R. Stewart, an officer of AbbVie, filed a Form 144 notice of intent to sell 40,619 shares…
This is a routine insider sale notice tied to a same-day option exercise, likely for tax or diversification purposes. The amount is immaterial relative to AbbVie's market cap. Monitor for the actual…
- NEUTRAL 8-KNov 2, 2026
AbbVie disclosed that Class II director Jennifer L. Davis resigned from the board effective…
Monitor for any subsequent announcement of a new board appointment, but this departure is routine and unlikely to affect operations or strategy.
- BULLISH 8-KOct 30, 2026
AbbVie reported Q3 2026 adjusted diluted EPS of $3.82, beating the $3.77 consensus by 1.3%, and…
The raised guidance and strong operational beat across immunology and neuroscience signal sustained momentum. Watch for pipeline catalysts including Skyrizi SC induction approval in Crohn's and…
- BULLISH COURT-RULINGOct 29, 2026
The D.C. District Court granted AbbVie partial summary judgment, ruling that CMS misinterpreted…
The ruling is a final judgment on the statutory claim; the government may appeal. Watch for a notice of appeal or a motion for stay pending appeal. If the ruling stands, BOTOX is excluded from IRA…
All ABBV filing & press-release reports (22)
- 144 reportNov 9, 2026
- 8-K reportNov 2, 2026
- COURT-RULING reportOct 29, 2026
- 8-K reportOct 30, 2026
- INST-CLUSTER reportOct 16, 2026
- 8-K reportOct 15, 2026
- 8-K reportOct 5, 2026
- COURT-RULING reportSep 28, 2026
- COURT-RULING reportSep 14, 2026
- 8-K reportSep 3, 2026
- 8-K reportAug 5, 2026
- COURT-RULING reportAug 3, 2026
- INST-CLUSTER reportAug 2, 2026
- 8-K reportJul 31, 2026
- COURT-RULING reportJul 27, 2026
- 8-K reportJun 22, 2026
- COURT-RULING reportMay 18, 2026
- 8-K reportApr 29, 2026
- Canaccord Genuity initiates ABBV at Buy with $262 PT, +28.6% upsideApr 21, 2026
- 8-K reportApr 3, 2026
- DEFA14A reportMar 23, 2026
- CLUSTER reportMar 2, 2026